{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T12:25:45Z","timestamp":1795091145254,"version":"4.10.2"},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100012659","name":"Foundation for Innovative Research Groups of the National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013290","name":"National Key Research and Development Program of China Stem Cell and Translational Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013290","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jaad.2025.02.063","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T02:55:21Z","timestamp":1740538521000},"page":"46-54","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Characterization and treatment outcomes of biologic therapy in super-responders and biologic-refractory psoriasis patients: A single-center retrospective study in China"],"prefix":"10.1016","volume":"93","author":[{"given":"Yizhang","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongfang","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehong","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10275","key":"10.1016\/j.jaad.2025.02.063_bib1","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S0140-6736(21)00184-7","article-title":"Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis","volume":"397","author":"Ghoreschi","year":"2021","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jaad.2025.02.063_bib2","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/bjd\/ljad280","article-title":"How to define a 'super-responder' to biologics in psoriasis studies","volume":"189","author":"Thomas","year":"2023","journal-title":"Br J Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2025.02.063_bib3","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1111\/jdv.18474","article-title":"Super-response to guselkumab treatment in patients with moderate-to-severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator's Global Assessment scores predict complete skin clearance","volume":"36","author":"Reich","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.jaad.2025.02.063_bib4","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/bjd\/ljad446","article-title":"Characteristics of 'super responders' and 'super nonresponders' to first biologic monotherapy for psoriasis: a nested case-control study","volume":"190","author":"Mason","year":"2024","journal-title":"Br J Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2025.02.063_bib5","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1111\/jdv.18126","article-title":"Prevalence and characterization of treatment-refractory psoriasis and super-responders to biologic treatment: a nationwide study","volume":"36","author":"Loft","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"17","key":"10.1016\/j.jaad.2025.02.063_bib6","doi-asserted-by":"crossref","first-page":"5175","DOI":"10.3390\/jcm13175175","article-title":"Characterization of super-responder profile in chronic plaque psoriatic patients under guselkumab treatment: a long-term real-life experience","volume":"13","author":"Marcelli","year":"2024","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.jaad.2025.02.063_bib7","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2024.2331782","article-title":"Comparison between super-responders and non-super-responders in psoriasis under adalimumab treatment: a real-life cohort study on the effectiveness and drug survival over one-year","volume":"35","author":"Liu","year":"2024","journal-title":"J Dermatolog Treat"},{"issue":"5","key":"10.1016\/j.jaad.2025.02.063_bib8","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.jaad.2023.06.058","article-title":"Sociodemographic and clinical characteristics associated with multiple biologic failure in psoriasis: A 2015-2022 prospective cohort analysis of the CorEvitas psoriasis registry","volume":"89","author":"Jin","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2025.02.063_bib9","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s13555-023-00907-1","article-title":"Living with psoriasis vulgaris and multi-treatment failure: a patient and dermatologist perspective","volume":"13","author":"Spencer","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"14","key":"10.1016\/j.jaad.2025.02.063_bib10","doi-asserted-by":"crossref","first-page":"3992","DOI":"10.3390\/jcm13143992","article-title":"Blood-count-derived inflammatory markers as predictors of response to biologics and small-molecule inhibitors in psoriasis: a multicenter study","volume":"13","author":"Morariu","year":"2024","journal-title":"J Clin Med"},{"issue":"4","key":"10.1016\/j.jaad.2025.02.063_bib11","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1093\/bjd\/ljae147","article-title":"Insulin resistance impairs biologic agent response in moderate-to-severe plaque psoriasis: insights from a prospective cohort study in China","volume":"191","author":"Huang","year":"2024","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2025.02.063_bib12","first-page":"351","article-title":"Multi-failure psoriasis patients: characterization of the patients and response to biological therapy in a multicenter Italian cohort","volume":"63","author":"Viola","year":"2024","journal-title":"Int J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2025.02.063_bib13","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/ard-2023-225087","article-title":"Time to address the challenge of difficult to treat psoriatic arthritis: results from an international survey","volume":"83","author":"Marzo-Ortega","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.jaad.2025.02.063_bib14","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1038\/jid.2015.208","article-title":"Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)","volume":"135","author":"Warren","year":"2015","journal-title":"J Invest Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2025.02.063_bib15","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1007\/s00421-021-04668-7","article-title":"Transferring clinically established immune inflammation markers into exercise physiology: focus on neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio and systemic immune-inflammation index","volume":"121","author":"Walzik","year":"2021","journal-title":"Eur J Appl Physiol"},{"issue":"8","key":"10.1016\/j.jaad.2025.02.063_bib16","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1002\/oby.23503","article-title":"Measuring and estimating insulin resistance in clinical and research settings","volume":"30","author":"Gastaldelli","year":"2022","journal-title":"Obesity (Silver Spring)"},{"issue":"12","key":"10.1016\/j.jaad.2025.02.063_bib17","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1111\/exd.14731","article-title":"\"Superresponders\" at biologic treatment for psoriasis: A comparative study among IL17 and IL23 inhibitors","volume":"32","author":"Mastorino","year":"2023","journal-title":"Exp Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2025.02.063_bib18","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1001\/jamadermatol.2024.1677","article-title":"Clinical characteristics associated with response to biologics in the treatment of psoriasis: a meta-analysis","volume":"160","author":"Hjort","year":"2024","journal-title":"JAMA Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2025.02.063_bib19","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s40257-022-00722-y","article-title":"Drug survival of interleukin (IL)-17 and IL-23 inhibitors for the treatment of psoriasis: a retrospective multi-country, multicentric cohort study","volume":"23","author":"Torres","year":"2022","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2025.02.063_bib20","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1517\/14712598.2014.900541","article-title":"The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial","volume":"14","author":"Al-Mutairi","year":"2014","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"10.1016\/j.jaad.2025.02.063_bib21","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jid.2018.07.028","article-title":"Defining the therapeutic range for adalimumab and predicting response in psoriasis: a multicenter prospective observational cohort study","volume":"139","author":"Wilkinson","year":"2019","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2025.02.063_bib22","article-title":"Clinical characteristics of patients with a family history of psoriasis: an observational epidemiological study in Chinese Han population","volume":"11","author":"Cao","year":"2024","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"10.1016\/j.jaad.2025.02.063_bib23","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2024.2321188","article-title":"Short-term effectiveness and potential factors of ustekinumab based on real-world data in Chinese psoriasis patients","volume":"35","author":"Li","year":"2024","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"10.1016\/j.jaad.2025.02.063_bib24","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jaad.2021.06.883","article-title":"Comorbid obesity and history of diabetes are independently associated with poorer treatment response to biologics at 6 months: a prospective analysis in Corrona Psoriasis Registry","volume":"86","author":"Enos","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2025.02.063_bib25","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/bjd.18981","article-title":"Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)","volume":"183","author":"Yiu","year":"2020","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2025.02.063_bib26","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s12325-022-02379-9","article-title":"Comparative effectiveness of biologics across subgroups of patients with moderate-to-severe plaque psoriasis: results at week 12 from the PSoHO study in a real-world setting","volume":"40","author":"Lynde","year":"2023","journal-title":"Adv Ther"},{"issue":"4","key":"10.1016\/j.jaad.2025.02.063_bib27","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/jdv.12847","article-title":"Risk of non-alcoholic fatty liver disease in patients with psoriasis: a systematic review and meta-analysis","volume":"29","author":"Candia","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"10.1016\/j.jaad.2025.02.063_bib28","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1007\/s40618-022-01755-0","article-title":"Risk of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis: an updated systematic review and meta-analysis of observational studies","volume":"45","author":"Bellinato","year":"2022","journal-title":"J Endocrinol Invest"},{"issue":"5","key":"10.1016\/j.jaad.2025.02.063_bib29","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.3390\/ijms25052660","article-title":"Intersecting pathways: nonalcoholic fatty liver disease and psoriasis duet-a comprehensive review","volume":"25","author":"Costache","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaad.2025.02.063_bib30","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2015.80","article-title":"Nonalcoholic fatty liver disease","volume":"1","author":"Brunt","year":"2015","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"10.1016\/j.jaad.2025.02.063_bib31","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.jaad.2022.04.060","article-title":"Secukinumab improves mild-to-moderate psoriasis: A randomized, placebo-controlled exploratory clinical trial","volume":"88","author":"Kim","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2025.02.063_bib32","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00403-024-02972-8","article-title":"Evaluation of the inflammatory parameters as potential biomarkers of systemic inflammation extent and the disease severity in psoriasis patients","volume":"316","author":"Zhang","year":"2024","journal-title":"Arch Dermatol Res"},{"issue":"9","key":"10.1016\/j.jaad.2025.02.063_bib33","doi-asserted-by":"crossref","first-page":"769","DOI":"10.2340\/00015555-3200","article-title":"IL-17A inhibitor switching\u2014efficacy of ixekizumab following secukinumab failure. A single-center experience","volume":"99","author":"Sherman","year":"2019","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"10.1016\/j.jaad.2025.02.063_bib34","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jaad.2020.07.085","article-title":"Efficacy of a second interleukin 17 inhibitor in patients with psoriasis: a systematic review and meta-analysis","volume":"84","author":"Loft","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"19","key":"10.1016\/j.jaad.2025.02.063_bib35","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3714","article-title":"Ixekizumab survival in heavily pretreated patients with psoriasis: a two-year single-centre retrospective study","volume":"100","author":"Sherman","year":"2020","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"10.1016\/j.jaad.2025.02.063_bib36","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jaad.2019.03.048","article-title":"Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis","volume":"81","author":"Egeberg","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2025.02.063_bib37","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.jaad.2023.06.022","article-title":"Association between complete skin clearance (psoriasis area and severity index 100) and drug survival of biologics in patients with chronic plaque psoriasis: a single-center retrospective study","volume":"89","author":"Song","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2025.02.063_bib38","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.jaad.2020.12.010","article-title":"Paradoxical eruptions to targeted therapies in dermatology: a systematic review and analysis","volume":"86","author":"Murphy","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2025.02.063_bib39","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/bjd.17779","article-title":"Eczematous eruption during anti-interleukin 17 treatment of psoriasis: an emerging condition","volume":"181","author":"Napolitano","year":"2019","journal-title":"Br J Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2025.02.063_bib40","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1111\/jdv.16246","article-title":"Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review","volume":"34","author":"Al-Janabi","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225003585?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225003585?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T02:46:36Z","timestamp":1766112396000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962225003585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0190962225003585"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2025.02.063","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization and treatment outcomes of biologic therapy in super-responders and biologic-refractory psoriasis patients: A single-center retrospective study in China","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2025.02.063","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}